Literature DB >> 26635211

Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?

Per Soelberg Sørensen1.   

Abstract

A randomized, double-blind, phase III trial of generic glatiramer acetate has shown equivalent efficacy and safety compared with the approved formulation, Copaxone. The impact of approval of generic glatiramer acetate, however, will mainly depend on the pricing of the drug.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26635211     DOI： 10.1038/nrneurol.2015.224

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

Review 1.  The clinico-radiological paradox in multiple sclerosis revisited.

Authors:  Frederik Barkhof
Journal:  Curr Opin Neurol       Date:  2002-06       Impact factor: 5.710

2.  Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.

Authors:  Dennis Bourdette; Daniel Hartung
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

3.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Authors:  Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

4.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

5.  GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.

Authors:  Jerry S Wolinsky; T Erik Borresen; Dennis W Dietrich; Daniel Wynn; Yulia Sidi; Joshua R Steinerman; Volker Knappertz; Scott Kolodny
Journal:  Mult Scler Relat Disord       Date:  2015-06-14       Impact factor: 4.339

6.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

7.  Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Authors:  Fred D Lublin; Stacey S Cofield; Gary R Cutter; Robin Conwit; Ponnada A Narayana; Flavia Nelson; Amber R Salter; Tarah Gustafson; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2013-03-11       Impact factor: 10.422

8.  Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Authors:  Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffery; Steven R Schwid; Bettina Stubinski; Bernard M J Uitdehaag
Journal:  Lancet Neurol       Date:  2008-09-11       Impact factor: 44.182

9.  Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Jeffrey Cohen; Anna Belova; Krzysztof Selmaj; Christian Wolf; Maria Pia Sormani; Janine Oberyé; Evelyn van den Tweel; Roel Mulder; Norbert Koper; Gerrit Voortman; Frederik Barkhof
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

10.  250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

Authors:  Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; P O'Connor; M Filippi; B Arnason; S Cook; D Goodin; H-P Hartung; H-P Harung; L Kappos; D Jeffery; G Comi
Journal:  Lancet Neurol       Date:  2009-09-02       Impact factor: 44.182
  10 in total
  2 in total

Review 1.  Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.

Authors:  Chong Guo; Chaoying Song; Jiali Zhang; Yisong Gao; Yuying Qi; Zongyao Zhao; Chengfu Yuan
Journal:  Genes Dis       Date:  2020-12-01

Review 2.  A Comprehensive Review on Copemyl®.

Authors:  Pietro Annovazzi; Antonio Bertolotto; Vincenzo Brescia Morra; Claudio Gasperini; Enrico Montanari; Pierluigi Navarra; Francesco Patti; Maria Pia Sormani; Angelo Ghezzi
Journal:  Neurol Ther       Date:  2017-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.